https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Compared with baseline, scores of SF-MPQ and CMSS significantly decreased in both groups (P0.05), and no significant difference was observed between the two groups in the 3rd and 6th menstrual cycles (P0.05). The total occurrence rate of AEs in MR group was 2.1%, which was significantly lower than MM group (7.2%, P0.05). MR has the same effect as MM at SF-MPQ and CMSS in patients with PD. However, MR is safer than MM (Trial registration No. ChiCTR1800018236). MR has the same effect as MM at SF-MPQ and CMSS in pa
Like
Comment
Share
